NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRXP NRX Pharmaceuticals Inc.

Trading 01-23 11:27:32 EST

2.18

-0.16

-6.94%

High2.34	Low2.17	Vol375.20K
Open2.30	D1 Closing2.34	Amplitude7.27%
Mkt Cap64.47M	Tradable Cap47.54M	Total Shares29.61M
T/O828.12K	T/O Rate1.72%	Tradable Shares21.83M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRXP","market":"US","secType":"STK","nameCN":"NRX Pharmaceuticals Inc.","latestPrice":2.1775,"timestamp":1769185649646,"preClose":2.34,"halted":0,"volume":375197,"delay":0,"changeRate":-0.0694444444444443,"floatShares":21834000,"shares":29605200,"eps":-2.31,"marketStatus":"Trading","change":-0.1625,"latestTime":"01-23 11:27:32 EST","open":2.3,"high":2.34,"low":2.17,"amount":828122.061702,"amplitude":0.07265,"askPrice":2.18,"askSize":500,"bidPrice":2.17,"bidSize":275,"shortable":3,"etf":0,"ttmEps":-2.31,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1769202000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":2.34,"preHourTrading":{"tag":"盘前","latestPrice":2.28,"preClose":2.34,"latestTime":"09:25 EST","volume":3050,"amount":6907.72967,"timestamp":1769178300027,"change":-0.06,"changeRate":-0.025641,"amplitude":0.060256},"postHourTrading":{"tag":"盘后","latestPrice":2.34,"preClose":2.34,"latestTime":"18:54 EST","volume":7490,"amount":17438.9208,"timestamp":1769126059586,"change":0,"changeRate":0,"amplitude":0.034188},"volumeRatio":1.201136,"impliedVol":0.4488,"impliedVolPercentile":0.0319},"requestUrl":"/m/hq/s/NRXP/tweets","defaultTab":"tweets","newsList":[{"id":"2603599802","title":"NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2603599802","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603599802?lang=en_us&edition=fundamental","pubTime":"2026-01-16 20:03","pubTimestamp":1768564980,"startTime":"0","endTime":"0","summary":"WILMINGTON, Del., Jan.  16, 2026  (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) (the “Company”), a clinical-stage biopharmaceutical company, today announced that it will hold its annual ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/16/3220242/0/en/NRx-Pharmaceuticals-Nasdaq-NRXP-Announces-2025-Annual-Meeting-Date-and-Record-Date.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2603603772","title":"NRX Pharmaceuticals Price Target Maintained With a $25.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2603603772","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603603772?lang=en_us&edition=fundamental","pubTime":"2026-01-15 17:55","pubTimestamp":1768470900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 15, 2026 04:55 ET (09:55 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2603618007","title":"NRX Pharmaceuticals Submits Real-World Data to FDA for Accelerated Approval of NRX-100","url":"https://stock-news.laohu8.com/highlight/detail?id=2603618007","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603618007?lang=en_us&edition=fundamental","pubTime":"2026-01-14 20:03","pubTimestamp":1768392192,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals, Inc. has announced the submission of Real World Evidence  from over 70,000 patients in support of its application for Accelerated Approval of NRX-100  under Fast Track Designation for the treatment of suicidal ideation in depression and bipolar depression. The submission follows a recent policy change by the FDA allowing the inclusion of de-identified patient data in regulatory filings. Currently, there is no medicine approved specifically for the treatment of suicidal ideation, with Electroshock Therapy being the only FDA-approved intervention for this condition. The data, licensed from Osmind, will be presented to the FDA as part of the application process.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharm","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL3cvGp9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014039.USD","NDAQ","LU2095319765.USD","NRXP","BK4585","BK4588","LU2210149790.SGD","BK4112","SG9999014013.SGD","SG9999014005.SGD","SG9999014021.USD","IE00BKPKM429.USD","BK4007","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2603180976","title":"NRX Pharmaceuticals (Nasdaq:Nrxp) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to Be Submitted to the FDA in Support of NRX-100 Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2603180976","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603180976?lang=en_us&edition=fundamental","pubTime":"2026-01-14 20:03","pubTimestamp":1768392180,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nTUA9GLHTK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2601884929","title":"NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2601884929","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601884929?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:41","pubTimestamp":1767620460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 05, 2026 08:41 ET (13:41 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2601688546","title":"NRX Pharmaceuticals and neurocare Group Launch Nationwide Network for Integrated Mental Health Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2601688546","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601688546?lang=en_us&edition=fundamental","pubTime":"2026-01-05 19:57","pubTimestamp":1767614234,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals Inc. has announced a partnership with neurocare Group AG to establish a nationwide network of clinics offering integrated neuroplastic care for Depression, PTSD, and other serious mental health disorders. The collaboration will merge neurocare’s expertise in neuromodulation technology with NRx’s neuroplastic drug development program, creating unified treatment protocols that combine Transcranial Magnetic Stimulation , ketamine and other neuroplastic drugs, hyperbaric oxygen therapy, and supportive psychotherapy. The initiative leverages neurocare’s network of over 400 Apollo TMS devices across the United States and aims to bring integrated treatment within driving distance of any American home by the end of 2026, with an initial focus on First Responders, Active Duty Military, and Veterans. The program also seeks to provide a single point of accountable care to payers and expand contracts with commercial and governmental health programs.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDLc2RhDB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4112","SG9999014039.USD","LU2210149790.SGD","SG9999014021.USD","IE00BGHQF748.EUR","BK4588","IE00B3QW5Z07.USD","NRXP","SG9999014005.SGD","BK4007","BK4585","IE00BKPKM429.USD","LU0314104364.USD","SG9999014013.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","NDAQ"],"gpt_icon":0},{"id":"2600057633","title":"NRX Pharmaceuticals Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2600057633","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600057633?lang=en_us&edition=fundamental","pubTime":"2026-01-02 17:59","pubTimestamp":1767347940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 02, 2026 04:59 ET (09:59 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2595816753","title":"NRX Pharmaceuticals Eliminates All Debt Through Equity Conversion","url":"https://stock-news.laohu8.com/highlight/detail?id=2595816753","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595816753?lang=en_us&edition=fundamental","pubTime":"2025-12-30 05:31","pubTimestamp":1767043865,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc. has announced the elimination of all balance sheet debt following a strategic equity conversion. The company repaid its remaining $5.4 million debt to Anson Funds, LLC by converting the debt into common stock, with no additional warrants or adjustment provisions involved. With this transaction, NRX Pharmaceuticals expects to end 2025 with no outstanding convertible debt, positioning the company for accelerated growth and potential drug approvals and clinic expansions in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securitie","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL9l56p6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2592087229","title":"NRX Pharmaceuticals Eliminates Remaining $5.4 Million Debt Through Equity Conversion, Achieves Debt-Free Balance Sheet","url":"https://stock-news.laohu8.com/highlight/detail?id=2592087229","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592087229?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:05","pubTimestamp":1766059513,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc. has announced the elimination of all balance sheet debt following a strategic equity conversion. The company repaid the remaining $5.4 million in debt to Anson Funds, LLC through the conversion of common stock, with no additional warrants or adjustment provisions involved in the transaction. With this move, NRX Pharmaceuticals anticipates ending the 2025 calendar year with no outstanding convertible debt. The company believes this debt-free position will support accelerated growth and potential drug approvals and clinic expansions in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 18, 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL8861hn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","LU0314104364.USD","NRXP","BK4585","IE00B3QW5Z07.USD","BK4588","IE00BGHQF748.EUR","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014039.USD","SG9999014005.SGD","LU2210149790.SGD","BK4007"],"gpt_icon":0},{"id":"2591617981","title":"NRX Pharmaceuticals Price Target Maintained With a $40.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2591617981","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591617981?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:19","pubTimestamp":1765887540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2025 07:19 ET (12:19 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2588904935","title":"BRIEF-Nrx Pharmaceuticals Inc - Amends Ind Filing For Nrx-101 To Include Tms Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2588904935","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588904935?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:06","pubTimestamp":1764767201,"startTime":"0","endTime":"0","summary":"BRIEF-Nrx Pharmaceuticals Inc - Amends Ind Filing For Nrx-101 To Include Tms UseDec 3 (Reuters) - NRX Pharmaceuticals Inc NRXP.O:NRX PHARMACEUTICALS INC - AMENDS IND FILING FOR NRX-101 TO INCLUDE TMS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X90EL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2588704374","title":"NRX Pharmaceuticals Inc - Amends Ind Filing for NRX-101 to Include Tms Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2588704374","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588704374?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:04","pubTimestamp":1764763477,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X90EL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2588805408","title":"NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2588805408","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588805408?lang=en_us&edition=fundamental","pubTime":"2025-12-02 23:30","pubTimestamp":1764689400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 02, 2025 10:30 ET (15:30 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2588552800","title":"NRX Pharmaceuticals Inc - Gdufa Goal Date Set for July 29, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588552800","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588552800?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:30","pubTimestamp":1764682218,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X802P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2588405528","title":"NRX Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of Anda for Ketafree™, a Preservative-Free Iv Ketamine","url":"https://stock-news.laohu8.com/highlight/detail?id=2588405528","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588405528?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:30","pubTimestamp":1764682218,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X802P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2588055215","title":"NRX Pharmaceuticals Inc - Applies for Ketafree as Proprietary  Product Name","url":"https://stock-news.laohu8.com/highlight/detail?id=2588055215","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588055215?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:30","pubTimestamp":1764682218,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X802P:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2588055751","title":"FDA Accepts NRx Pharmaceuticals' ANDA for KETAFREE with Review Goal Date Set","url":"https://stock-news.laohu8.com/highlight/detail?id=2588055751","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588055751?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:30","pubTimestamp":1764682218,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration  has received and deemed substantially complete its Abbreviated New Drug Application  for KETAFREE, a preservative-free intravenous ketamine formulation. The FDA has assigned a Generic Drug User Fee Amendments  goal date of July 29, 2026, for completion of the final review and potential marketing approval. KETAFREE is positioned as the first preservative-free ketamine formulation without Benzethonium Chloride, a preservative not recognized as safe by the FDA. The regulatory review is specific to NRx Pharmaceuticals Inc.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via G","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL3KzRxt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU2210149790.SGD","NRXP","BK4112","LU0314104364.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","IE00BKPKM429.USD","LU2210150020.SGD","BK4585","LU2095319765.USD","NDAQ"],"gpt_icon":0},{"id":"2588539720","title":"NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2588539720","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588539720?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:03","pubTimestamp":1764594180,"startTime":"0","endTime":"0","summary":"WILMINGTON, Del., Dec.  01, 2025  (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, the “Company”, “NRx”), a clinical-stage biopharmaceutical company and HOPE Therapeutics, an interventiona","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196980/0/en/NRx-Pharmaceuticals-NASDAQ-NRXP-and-HOPE-Therapeutics-to-Present-at-NobleCon21-Noble-Capital-Markets-Twenty-First-Annual-Emerging-Growth-Equity-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBL","BK4139",".IXIC","EQR","BK4585","MNQmain","USAW.SI","NVIW.SI","BK4588","QID","BK4215","TQQQ","BK4007","QLD","USJW.SI","NRXP","LENZ","BK4539","NQmain","SQQQ","HOPE","PSQ","TSYW.SI","BK4211"],"gpt_icon":1},{"id":"2584392349","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: NRX Pharmaceuticals (NRXP), LifeMD (LFMD) and Hims & Hers Health (HIMS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584392349","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584392349?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:10","pubTimestamp":1763464213,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on NRX Pharmaceuticals (NRXP – Research Report), LifeMD (LFMD – Rese...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-nrx-pharmaceuticals-nrxp-lifemd-lfmd-and-hims-hers-health-hims-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-nrx-pharmaceuticals-nrxp-lifemd-lfmd-and-hims-hers-health-hims-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","HCSG","LU0128526141.USD","BK4588","BK4183","NRXP","BK4585","LFMD","XBI","BK4196","LABU","XLV","HIMS","LU0029874061.USD","BK4007","BK4167","BK4581"],"gpt_icon":0},{"id":"2584267823","title":"NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q3 Results and Advances NRX-100 and NRX-101 Regulatory Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2584267823","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584267823?lang=en_us&edition=fundamental","pubTime":"2025-11-18 01:00","pubTimestamp":1763398814,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, November 17th, 2025, FinanceWire NRx Pharmaceuticals (NASDAQ: NRXP) reported third-quarter 2025 results and outlined ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/nrx-pharmaceuticals-nasdaq-nrxp-reports-q3-results-and-advances-nrx-100-and-nrx-101-regulatory-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/nrx-pharmaceuticals-nasdaq-nrxp-reports-q3-results-and-advances-nrx-100-and-nrx-101-regulatory-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSYW.SI","SQQQ","MNQmain","USAW.SI","NVIW.SI","NRXP",".IXIC","QLD","PSQ","QID","BK4007","TQQQ","NQmain","USJW.SI"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.salbergco.com","stockEarnings":[{"period":"1week","weight":0.0884},{"period":"1month","weight":-0.0209},{"period":"3month","weight":-0.2571},{"period":"6month","weight":-0.22},{"period":"1year","weight":-0.3276},{"period":"ytd","weight":-0.1365}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0173},{"period":"6month","weight":0.0814},{"period":"1year","weight":0.1361},{"period":"ytd","weight":0.0104}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.056813},{"month":2,"riseRate":0.25,"avgChangeRate":-0.099886},{"month":3,"riseRate":0.25,"avgChangeRate":-0.079214},{"month":4,"riseRate":0.25,"avgChangeRate":-0.225146},{"month":5,"riseRate":0.75,"avgChangeRate":0.071255},{"month":6,"riseRate":0.4,"avgChangeRate":-0.166652},{"month":7,"riseRate":0.4,"avgChangeRate":0.039708},{"month":8,"riseRate":0.2,"avgChangeRate":-0.14211},{"month":9,"riseRate":0.4,"avgChangeRate":-0.012776},{"month":10,"riseRate":0.6,"avgChangeRate":0.037482},{"month":11,"riseRate":0.4,"avgChangeRate":0.048439},{"month":12,"riseRate":0.6,"avgChangeRate":0.121824}],"exchange":"NASDAQ","name":"NRX Pharmaceuticals Inc.","nameEN":"NRX Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NRX Pharmaceuticals Inc.(NRXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NRX Pharmaceuticals Inc.,NRXP,NRX Pharmaceuticals Inc.股票,NRX Pharmaceuticals Inc.股票老虎,NRX Pharmaceuticals Inc.股票老虎国际,NRX Pharmaceuticals Inc.行情,NRX Pharmaceuticals Inc.股票行情,NRX Pharmaceuticals Inc.股价,NRX Pharmaceuticals Inc.股市,NRX Pharmaceuticals Inc.股票价格,NRX Pharmaceuticals Inc.股票交易,NRX Pharmaceuticals Inc.股票购买,NRX Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NRX Pharmaceuticals Inc.(NRXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction